Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2024 Oct 30;14(1):26150.
doi: 10.1038/s41598-024-75013-z.

Assessment of disability and disease burden in neuromyelitis optica spectrum disorders in the CIRCLES Cohort

Affiliations
Observational Study

Assessment of disability and disease burden in neuromyelitis optica spectrum disorders in the CIRCLES Cohort

Shervin Gholizadeh et al. Sci Rep. .

Abstract

Neuromyelitis optica spectrum disorders (NMOSD) comprise autoimmune diseases imposing substantial disability. We compared an NMOSD-targeted disability assessment of mobility, vision, and self-care domains (individually and composite) with the multiple sclerosis-targeted Expanded Disability Status Scale (EDSS) to assess NMOSD disease burden. An overall cohort (n = 505) and a subset of these patients with an enriched dataset (n = 198) were analyzed from the CIRCLES longitudinal, observational database of patients with AQP4-IgG-seropositive or -seronegative NMOSD in North America. Multinomial modeling was used to identify temporal correlates of disability improvement, stability, and worsening. Prior on-study relapse correlated with worsening mobility (OR, 3.08; 95% CI: 1.61-5.90), vision (OR, 3.99; 95% CI: 2.03-7.86), self-care disability (OR, 1.90; 95% CI: 1.07-3.38), and mean composite index disability (OR, 4.20; 95% CI: 1.71-10.34). Higher vision disability was associated with Black race, shorter time on-study, and AQP4-IgG-seropositive status in patients ≥ 18 years (p < 0.05). Disease onset phenotype and sex correlated with pain interference (p < 0.05). These correlates of NMOSD disability were undetected by EDSS. The CIRCLES real-world experience supports the need for NMOSD-specific disability assessment to improve recognition of disease burden, facilitate proactive clinical management, offer insights into resilience, and inform clinical trial design.

PubMed Disclaimer

Conflict of interest statement

The CIRCLES study was sponsored by The Guthy-Jackson Charitable Foundation. The present study was funded by Genentech, Inc. S. Gholizadeh is an employee of Genentech, Inc., and shareholder of F. Hoffmann-La Roche Ltd. A. Exuzides was an employee of Genentech, Inc., at the time of this study and manuscript preparation and is a shareholder of F. Hoffmann-La Roche Ltd. J. Sinnott has received research support from the Guthy-Jackson Charitable Foundation and the National Institutes of Health (NIH). C. Palmer and M. Waltz declare they have nothing to disclose. J. Rose has received research support from the National Multiple Sclerosis Society, Guthy-Jackson Charitable Foundation, NIH, Friends of MS, Biogen, and the US Department of Veterans Affairs. He has received intellectual property interests from a discovery or technology relating to health care. A. Jolley and J.M. Behne declare they have nothing to disclose. M.K. Behne has received personal compensation for serving as an independent contractor with the Guthy-Jackson Charitable Foundation. T.F. Blaschke has received personal compensation for serving as a consultant for Merck, the Guthy-Jackson Charitable Foundation, and the Bill and Melinda Gates Foundation. He has received personal compensation for serving as an officer or member of the board of directors for Durect. He has received personal compensation for serving as an editor, associate editor, or editorial advisory board member for Annual Reviews. He has received stock or ownership interest from Durect. He has received research support from the Bill and Melinda Gates Foundation. T.J. Smith has received personal compensation for serving as a consultant for Horizon and Immunovant. He has received personal compensation for serving on a scientific advisory or data safety monitoring board for Horizon. He has received intellectual property interests from a discovery or technology relating to health care. He is an advisor to the Guthy-Jackson Charitable Foundation. M.R. Yeaman has received personal compensation for serving on a scientific advisory committee for Genentech, Alexion, and Horizon. He has received research support from the NIH and US Department of Defense. He has received intellectual property interests from a discovery or technology relating to health care. He is an advisor to the Guthy-Jackson Charitable Foundation. K. Lewis declares she has nothing to disclose. L. Cook has received research support from the Centers for Disease Control and Prevention, Guthy-Jackson Charitable Foundation, Utah Highway Safety Office, and NIH.

Figures

Fig. 1
Fig. 1
Assessment of clinical variables associated with worsened and improved mobility (panels A and B) or vision (panels C and D) compared with stability (neither improved nor worsened). Odds ratio (95% CI); red = significant association (p<0.05); blue = non-significant association (p>0.05). AQP4-IgG, aquaporin-4 immunoglobulin G; AAR, annualized relapse rate; BPI, Brief Pain Inventory; MoCA, Montreal Cognitive Assessment; OR, odds ratio. Panels A & B represent results from patients in Cohort 1 for whom mobility data were available. Panels C & D represent results from patients in Cohort 1 for whom vision data were available. aHigher value of the score reflects worse disability. bReference, male; cReference, White. d Reference, age 35 to 48 years. e Reference, anti–AQP4-IgG seronegative. f Reference, 1 to 5 years. g Reference, ARR<0.25. h Reference, no prior on-study relapse. i Reference, no prior treatment change. j Binary variable indicating that MoCA, severity, and intensity scores are not available. k Reference, before 2017.
Fig. 2
Fig. 2
Assessment of clinical variables associated with self-care disability (panels A and B) or composite index score (panels C and D) as compared to stability (neither improved nor worsened). Odds ratio (95% CI); red = significant association (p<0.05); blue = non-significant association (p>0.05)AQP4-IgG, aquaporin-4 immunoglobulin G; AAR, annualized relapse rate; BPI, Brief Pain Inventory; MoCA, Montreal Cognitive Assessment; OR, odds ratio. Panels A & B represent results from patients in Cohort 1 for whom self-care data were available. Panels C & D represent results from patients in Cohort 1 for whom composite data were available. aHigher value of the score reflect worse disability. bReference, male; cReference, White. d Reference, age 35 to 48 years. e Reference, anti-AQP4–IgG seronegative. f Reference, 1 to 5 years. g Reference, ARR<0.25. h Reference, no prior on-study relapse. i Reference, no prior treatment change. j Binary variable indicating that MoCA, severity and intensity scores are not available. k Reference, before 2017.
Fig. 3
Fig. 3
The 7-point disability scales in the vision (A),a mobility (B),b and self-care (C)c domains, derived from patients with NMOSD.  NMOSD, neuromyelitis optica spectrum disorders.a Visual acuity based on best corrected eye (corrective lenses, pinhole, or refraction). b Mobility scores reflecting wheelchair or equivalent assume impaired ability to transfer, ambulate, or both. c Self-care disability score derives from a cumulative 3-point score for each activity of daily life assessed as follows: attend school/work or perform routine housework; bathing/showering; bowel/bladder management; personal grooming; dressing; food preparation; eating. Each of these activities is independently scored as 0 = independent; 1 = partially dependent; 2 = completely dependent. Scores for each of these activities are summed for the overall self-care disability score; higher scores indicate greater disability.

References

    1. Kim, S. M. et al. Differential diagnosis of neuromyelitis optica spectrum disorders. Ther. Adv. Neurol. Disord. 10, 265–289. 10.1177/1756285617709723 (2017). - PMC - PubMed
    1. Huda, S. et al. Neuromyelitis optica spectrum disorders. Clin. Med. (Lond). 19, 169–176. 10.7861/clinmedicine.19-2-169 (2019). - PMC - PubMed
    1. Wingerchuk, D. M. et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 85, 177–189. 10.1212/WNL.0000000000001729 (2015). - PMC - PubMed
    1. Hor, J. Y. et al. Epidemiology of neuromyelitis optica spectrum disorder and its prevalence and incidence worldwide. Front. Neurol. 11, 501. 10.3389/fneur.2020.00501 (2020). - PMC - PubMed
    1. Flanagan, E. P. et al. Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum. Ann. Neurol. 79, 775–783. 10.1002/ana.24617 (2016). - PMC - PubMed

Publication types

LinkOut - more resources